Additionally, we investigated whether our findings correlated with data from a phase I/II trial testing the BET inhibitor Molibresib as monotherapy in hematologic malignancies, which failed to induce significant clinical responses in AML18. This evidence concerns the gene DNER and hematologic disorder.